35 results about "Meningioma" patented technology

Provided herein are methods of improving glycemic control in an individual, wherein the methods comprise administering a menin inhibitor, such as ziftomenib or a pharmaceutically acceptable form thereof, to the individual.

The invention discloses a meningioma saliva microbial marker, a product and application of the meningioma saliva microbial marker, and belongs to the field of biological medicine. The saliva microbial marker is prepared from one or more of fusobacterium periodontium, neisseria microflavus, and Streptococcus cristatum, and the saliva microbial marker is prepared from one or more of the following components: the fusobacterium periodontium, the neisseria microflavus, and the Streptococcus cristatum, and the saliva microbial marker is prepared from one or more of the following components: the Saccharomyces cerevisiae, the Saccharomyces cerevisiae, the Saccharomyces cerevisiae and the Saccharomyces cristatum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the saliva microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

The invention discloses a meningioma enteric microbial marker, a product and application of the meningioma enteric microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and is characterized in that the enteric microbial marker comprises one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and the enteric microbial marker comprises one or more of parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

The invention discloses a positive ion saliva marker related to brain glioma and meningioma and application of the positive ion saliva marker, and relates to the field of biological medicine. The positive ion saliva marker is prepared from one or more of L-arabitol, 20-hydroxyarachidonic acid, sulfonate and palm oil acylethanolamide. The invention provides a kit which is used for detecting positive ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.

The application discloses a double-branch Raio gating graph aggregation multi-modal meningioma segmentation method, belongs to the cross technical field of computer vision and medical image processing, is used for meningioma segmentation, and comprises the following steps: preparing a data set, constructing a deep neural network model, and performing neural network training; inputting the data set into the trained deep neural network model; first inputting a double-branch multi-modal input module to output a multi-modal fusion feature tensor; then inputting the multi-modal fusion feature tensor into a hierarchical Swin Transformer encoder to output three-dimensional segmentation masks of enhanced tumors, tumor cores and whole tumor regions of meningioma. Through double-branch multi-modal input fusion, hierarchical Swin Transformer coding, edge perception modulation and Laplace gating graph aggregation, high-precision three-dimensional segmentation of enhanced tumors, tumor cores and whole tumor regions of meningioma is realized.

The present disclosure pertains to a method of predicting a molecular subtype of a tumor of a subject by (1) receiving preoperative imaging data of the tumor; (2) extracting one or more features of the imaging data; and (3) correlating the extracted features of the imaging data to a molecular subtype of the tumor. The methods may also include steps of outputting the molecular subtype of the tumor and implementing a treatment decision. The present disclosure also pertain to a computing device and a diagnostic test for predicting a molecular subtype of a tumor of a subject in accordance with the aforementioned methods.

An epigenetic silencer factor (ESF) for use in the treatment of cancer, or a polynucleotide encoding the same, wherein the ESF comprises a transcription factor DNA-binding domain functionally linked to at least one epigenetic effector domain, the transcription factor is an oncogenic transcription factor or a cancer-related transcription factor, and the cancer is selected from the group consisting of glioma, glioblastoma, medulloblastoma, astrocytoma, neuroblastoma, epithelioma, meningioma, retinoblastoma, rhabdomyosarcoma, lung cancer, prostate cancer, breast cancer, liver cancer, pancreatic cancer (e.g., human pancreatic ductal adenocarcinoma), bladder cancer, oropharyngeal cancer, kidney cancer, colon cancer (e.g., colon adenocarcinoma), colorectal cancer (CRC), or metastases of any of the foregoing.

The invention discloses a meningioma Ki67 classification method based on multi-modal medical data, which is applied to the field of image processing, and aims to solve the problem of overlarge calculation overhead during multi-modal fusion in the prior art based on image data, radiology data and radiomics data of multi-modal 3D MRI (three-dimensional magnetic resonance imaging) during meningioma Ki67 prediction. According to the method, iterative modal information fusion is carried out through the structured potential space and the cross attention mechanism, and the calculation complexity is remarkably reduced. According to the method, through dynamic weight distribution and iterative refinement, complementarity information between modes is effectively captured, redundant noise is suppressed, and the problem of feature dilution caused by mode length difference or simple superposition in a traditional splicing method is avoided; the compact representation of the potential space forces different modals to perform efficient interaction on the shared dimension, not only retains the key mode of cross-modal association, but also adaptively filters irrelevant contents through an attention mechanism, thereby realizing better balance on information density and semantic consistency, and improving the accuracy of the information density and semantic consistency. And the method is especially suitable for processing real scenes with unbalanced modes or partial loss.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The invention discloses a positive ion saliva marker related to brain glioma and meningioma and application of the positive ion saliva marker, and relates to the field of biological medicine. The positive ion saliva marker is prepared from one or more of N1, N12-diacetyl spermine, N-capryloyl dihydrosphingosine and perindopril. The invention provides a kit which is used for detecting positive ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

Systems and methods for digital pathology and mitosis detection in accordance with embodiments of the invention are illustrated. One embodiment includes a method for performing human-AI digital pathology. The method includes receiving at least one whole slide images (WSIs) of tissues, pre-processing the received WSIs, and generating meningioma grades for the received WSIs. The method further includes providing evidence justifying the generated meningioma grades, receiving updates regarding the provided evidence, and updating the meningioma grades based on the received updates.

The invention relates to a compound of formula (I), wherein, for example, - Z is representing a group (II), wherein R5 is representing NR6R7 group and wherein R6 and R7 represent independently a hydrogen - R4 is representing a O-aryl ring, - X is representing a NR2R3 group, wherein R2 and R3 are independently hydrogen and a (C1- C10)alkyl group, - R1 is representing a group (III), for its use in the prevention or the treatment of one of the following brain cancers chosen among: glioblastoma, astrocytoma, oligodendroglioma, medulloblastoma, ependymoma, meningioma, pineoblastoma, or in the prevention or the treatment of epilepsies or infantile epilepsies.

The application discloses a dental plaque microbial marker related to brain glioma and meningioma and an application thereof, and belongs to the field of biological medicine. The dental plaque microbial marker comprises one or more of Prevotella shahii, Capnocytophaga gingivalis, Mycobacterium gordonae, Leptothrix oralis and Ottowia. The application provides a kit comprising detection reagents for detecting the relative abundance of the dental plaque microbial marker. The application provides a product for diagnosing brain glioma and a computer program product related to brain glioma and meningioma. The product provided by the application has good feasibility and accuracy, and can be used as a new idea and approach for distinguishing brain glioma and meningioma.

The invention discloses an anion saliva metabolite marker related to meningioma, a product and application of the anion saliva metabolite marker, and relates to the field of biological medicine. The negative ion saliva metabolite marker comprises one or more of phosphatidyl ethanolamine Pe 32: 1, 1, 2-di-palm oil acyl-sn-glycerol-3-phosphoethanolamine, phosphatidyl ethanolamine Pe34: 2, 1, 2-di-palm oil acyl-sn-glycerol-3-phosphoethanolamine, 3-dehydroepiandrosterone sulfate and 1, 2-di-oleoyl-sn-glycerol-3-phosphoric acid, and the negative ion saliva metabolite marker comprises one or more of phosphatidyl ethanolamine Pe 32: 1, 1, 2-di-palm oil acyl-sn-glycerol-3-phosphoethanolamine, phosphatidyl ethanolamine Pe34: 2, 1, 2-di-palm oil acyl-sn-glycerol-3-phosphoethanolamine, 1, 2-di-palm oil acyl-sn-glycerol-3- The invention provides a kit which is used for detecting negative ion saliva metabolite markers related to meningioma and comprises a specific detection reagent. In addition, the invention also provides a computer program product which is specially used for evaluating meningioma. The products have good feasibility and accuracy, the risk of meningioma can be effectively evaluated, and a brand new powerful tool is provided for clinical diagnosis.

The invention discloses a negative ion saliva marker related to brain glioma and meningioma and application of the negative ion saliva marker, and relates to the field of biological medicine. The negative ion saliva marker is prepared from one or more of 1, 2-dioleoyl-sn-glycerol-3-phosphoric acid, N-acetyl-L-glutamic acid, arabitol, myristic acid, linolenic acid and hexanoic acid. The invention provides a kit, which is used for detecting negative ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.

The application discloses a meningioma automatic grading method based on multi-view image feature fusion, comprising the following steps: S1: for the model input end, the lesion image of Dicom format data is converted into PNG data without any image enhancement and data amplification processing, and is input into a multi-view image feature fusion model as three channels; S2: the full connection layer and the maximum pooling of ResNet are removed as the basic network of each view feature extraction, transfer learning is introduced, and a normalized attention module is added to the model to suppress the insignificant features of the related views, so that the best feature information of each view is extracted; S3: after the feature information extracted from each view is fused, the feature is re-extracted, and the interference information is further filtered, and the pre-training residual neural network model of the three different channels and the fusion network are used to compose the model, and the fusion model is trained in an end-to-end mode, so that the effect of accurately distinguishing low-grade meningioma and high-grade meningioma can be achieved.

The invention discloses a dental plaque microbial marker related to brain glioma and meningioma and application of the dental plaque microbial marker, and belongs to the field of biological medicine. The dental plaque microbial marker is prepared from one or more of prevotella vulgaris, carbon dioxide cytophaga gingivalis, meniscus expectogenes, oral cilia and otobacterium. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the dental plaque microbial marker. The invention provides a product for diagnosing brain glioma and a computer program product related to the brain glioma and meningioma. The product provided by the invention has good feasibility and accuracy, and can be used as a new idea and approach for distinguishing brain glioma and meningioma.

The present invention discloses a meningioma intestinal microbial marker, product, and application thereof, belonging to the field of biomedicine. The intestinal microbial marker includes one or more of Parabacteroides distasonis, Prevotella copri, Bifidobacterium adolescentis, and Streptococcus salivarius. The present invention provides a kit comprising a detection reagent for detecting the relative abundance of the intestinal microbial marker. The present invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the present invention has good feasibility and accuracy, can effectively assess the risk of meningioma, and provides a new tool for clinical diagnosis.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The invention discloses a positive ion saliva metabolite marker related to meningioma, a product and application of the positive ion saliva metabolite marker, and relates to the field of biological medicine. The positive ion saliva metabolite marker is prepared from one or more of 1-palmitoyl-2-glutaryl phosphatidylcholine, 2, 3, 5-triiodobenzene alcohol, beta-estradiol, cortisol, N-acetylcadaverine, prilocaine, octadecanoic acid, sulfamethoxam and rimsulfuron. The invention provides a kit which is used for detecting positive ion saliva metabolite markers related to meningioma and comprises a specific detection reagent. In addition, the invention also provides a computer program product which is specially used for evaluating meningioma. The products have good feasibility and accuracy, the risk of meningioma can be effectively evaluated, and a brand new powerful tool is provided for clinical diagnosis.

The invention discloses human meningioma radiotherapy-resistant cell strains IOMM-Lee-RR and CH157-RR, which are preserved in the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC NO.C202527 and CCTCC NO.C202528, are radiotherapy-resistant cell strains obtained after the human meningioma cell strains IOMM-Lee and CH157 are subjected to no less than 10 times of X-ray accumulative irradiation and subculture respectively, have remarkable radiotherapy-resistant characteristics, and can be used for preparing radiotherapy-resistant cell strains for treating meningioma. And a foundation is provided for further research on screening of radiotherapy resistance related genes and radiotherapy resistance molecular mechanisms of human meningioma, screening of radiotherapy resistance targets and improvement of radiotherapy sensitivity.

The invention provides a method and a system for predicting the growth risk of accidental asymptomatic meningioma. The method comprises the following steps: acquiring baseline clinical data, iconomic semantic feature data and iconomic feature data of a patient suffering from accidental asymptomatic meningioma; dividing the patient queue into a training set, a verification set and a test set, screening independent prediction factors significantly related to tumor growth, training a random survival forest model based on the training set, and performing optimization and verification in the verification set and the test set to generate an optimal model for predicting the individualized time-dependent growth risk; and inputting related data of a patient to be predicted into the optimal model, and outputting meningioma growth risk assessment results at different time points in the future. According to the invention, the technical problem that a patient with primary asymptomatic meningioma lacks an individualized natural growth trend prediction tool is solved.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.

The present invention discloses a salivary microbial marker for meningioma, a product, and its application, belonging to the field of biomedicine. The salivary microbial marker includes one or more of Fusobacterium periodonticum, Neisseria subflava, and Streptococcus cristatus. The present invention provides a kit comprising a detection reagent for detecting the relative abundance of the salivary microbial marker. The present invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the present invention has good feasibility and accuracy, can effectively assess the risk of meningioma, and provides a new tool for clinical diagnosis.

The present application relates to a meningioma infiltration boundary resection strategy optimization method, which uses the stress and strain response difference during intraoperative tissue traction and suction operation to mark the biomechanical abnormal area in space; constructs a mechanical residual atlas; extracts the local tissue compliance critical point as the physiological landmark of the infiltration boundary; identifies the high adaptability channel in the three-dimensional tissue atlas; makes partition modeling for the structural impedance of different regions; constructs a boundary evolution stability hot area map, maps the boundary prediction result back to the current operation scene, and is used to judge whether the resection range needs to be expanded; after each tissue stripping or resection, the corresponding regional tissue deformation rate, blood supply flow rate and temperature diffusion mode indicators are collected as the reflection of the intraoperative boundary stress response, which is used to evaluate whether the high-risk area has been touched by the resection behavior; once the boundary stress index exceeds the preset threshold, the system freezes the path segment, calculates the alternative path, improves the accuracy of boundary identification, and reduces the damage to the functional area and the recurrence risk.

The application discloses application of RPL27A gene and / or RPL27A protein in preparation of a meningioma treatment drug. The application provides a new meningioma treatment target, and the RPL27A has a significant anti-meningioma function, can inhibit occurrence, development and metastasis of meningioma, and has wide clinical application value for development of a new meningioma diagnosis marker and a treatment drug.

The invention provides application of a compound in preparation of a medicine for inhibiting G3BPs, and belongs to the technical field of biological medicine. The medicine is used for treating tumors, neurodegenerative diseases or virus infection; the tumors comprise any one or a combination of lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, pancreatic cancer, cervical cancer, skin cancer, osteosarcoma, liposarcoma, smooth muscle sarcoma, leukemia, lymphoma, multiple myeloma, glioma, meningioma, testicular cancer, endometrial cancer, cervical cancer, ovarian cancer, melanoma, thyroid cancer, kidney cancer or bladder cancer. When the compound shown in the formula (I) is combined with different anti-tumor drugs in various tumor cells, the sensitivity of the cells to the anti-tumor drugs can be improved, so that the drug resistance of the tumor cells is reduced.

The application discloses a meningioma Ki67 classification method based on multi-modal medical data, applied to the field of image processing, aiming at the image data, radiology data and radiomics data based on 3D MRI with multiple modes during meningioma Ki67 prediction, and the existing technology has the problem of too large calculation overhead during multi-modal fusion; the application significantly reduces the calculation complexity through iterative modal information fusion of structured latent space and cross attention mechanism. It effectively captures the complementary information between modes through dynamic weight distribution and iterative refinement, while suppressing redundant noise, avoiding the feature dilution problem caused by mode length difference or simple superposition in the traditional splicing method; the compact representation of the latent space forces different modes to interact efficiently in the shared dimension, not only retaining the key patterns of cross-modal correlation, but also adaptively filtering irrelevant content through the attention mechanism, thereby achieving a better balance in information density and semantic consistency, especially suitable for processing real scenes with mode imbalance or partial loss.